UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities
In a report published Thursday, Citigroup analyst Jonathan Eckard reiterated a Buy rating on Alkermes PLC (NASDAQ: ALKS), and raised the price target from $38.00 to $43.00.
In the report, Citigroup noted, “We are adding ALKS to the Citi Focus List and increasing our target price on ALKS to $43 from $38 based on our increased estimates for late-stage programs, introduction of estimates for earlier stage programs, and lower outyear tax rate. We believe there are several ALKS programs with significant commercial potential. Considering the breadth of interesting programs in the company's pipeline, we believe that ALKS' relative valuation is discounted compared to other mid-cap biotech companies within the same range of market capitalization.”
Alkermes PLC closed on Wednesday at $32.62.
Latest Ratings for ALKS
|Dec 2014||Credit Suisse||Maintains||Outperform|
|Apr 2014||Mizuho Securities||Upgrades||Neutral||Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.